Global Buerger’s Disease Diagnosis Market
Global Buerger’s Disease Diagnosis Market

Buerger’s Disease Diagnosis Comprehensive Study by Type (Blood Tests, The Allen’s Test, Angiogram (CT Scan, MRI Scan, X-Ray, Others), Tissue Biopsy, Others), Treatment (Smoking Cessation, Other Treatments (Medications, Intermittent Compression of the Arms and Legs, Spinal Cord Stimulation, Surgery, Amputation, Therapeutic Angiogenesis, and Others)), End User (Hospitals, Clinics, Medical Research Centers, Academic Institutes, Others) Players and Region - Global Market Outlook to 2026

Buerger’s Disease Diagnosis Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 204 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Buerger’s Disease Diagnosis Market?

Buerger's disease is a hereditary disease that primarily affects young and middle-aged male smokers. Peripheral vascular disease is characterized by narrowing or obstruction (occlusion) of the veins and arteries of the extremities, resulting in a reduced blood supply to these areas. The legs are more commonly affected than the arms. The increased incidence of tobacco-using patients is one of the factors driving the buerger's disease treatment market forward.

The market study is being classified by Type (Blood Tests, The Allen’s Test, Angiogram (CT Scan, MRI Scan, X-Ray, Others), Tissue Biopsy and Others) and major geographies with country level break-up.

FUJIFILM Holdings Corporation (Japan), General Electric Company (United States), Koninklijke Philips N.V. (Netherlands), pluristem (Israel), Shimadzu Corporation (Japan), Siemens Healthcare GmbH (Germany), STEMPEUTICS RESEARCH PVT LTD (India), Toshiba Medical Corporation (Japan) and t2cure GmbH (Germany) are some of the key players profiled in the study.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Buerger’s Disease Diagnosis market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Buerger’s Disease Diagnosis market by Type, Application and Region.

On the basis of geography, the market of Buerger’s Disease Diagnosis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Surge in Awareness about Tobacco Addiction among Manufacturers and Governments Smoking Cessation Campaigns

Market Trend
  • Rising Clinical Trials

Restraints
  • Low Awareness of Addiction Care Products in Developed Countries

Opportunities
  • Growing Research Funding
  • Approvals for New Treatments or Therapies

Challenges
  • Side Effects of Some Therapies


In Mar 2021, The FDA granted orphan drug designation to CLBS12, an investigational nongene-edited cell therapy for the treatment of Buerger’s disease, according to the agent’s manufacturer.


Key Target Audience
Buerger’s disease diagnostic and treatment supplies companies, Buerger’s disease diagnostic and treatment supplies providers, Medical research laboratories, Research and Development (R&D) Companies, Market Research and Consulting Service Providers, Potential Investors, New Entrants & Investors, Research, Education & Training institutions, Analysts and Strategic Business Planners, Venture Capitalists and Private Equity Firms and Government Bodies

Frequently Asked Questions (FAQ):

1. Which factors would majorly drive the Buerger’s Disease Diagnosis Market?
"Surge in Awareness about Tobacco Addiction among Manufacturers and Governments Smoking Cessation Campaigns" is seen as one of major growth factors of Buerger’s Disease Diagnosis Market in years to come.

2. Can we have customized study for Buerger’s Disease Diagnosis Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. Which region will lead the Global Buerger’s Disease Diagnosis Market?
will lead the Buerger’s Disease Diagnosis Market.
Report Objectives / Segmentation Covered
By Type
  • Blood Tests
  • The Allen’s Test
  • Angiogram (CT Scan, MRI Scan, X-Ray, Others)
  • Tissue Biopsy
  • Others
By Treatment
  • Smoking Cessation
  • Other Treatments (Medications, Intermittent Compression of the Arms and Legs, Spinal Cord Stimulation, Surgery, Amputation, Therapeutic Angiogenesis, and Others)

By End User
  • Hospitals
  • Clinics
  • Medical Research Centers
  • Academic Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Surge in Awareness about Tobacco Addiction among Manufacturers and Governments Smoking Cessation Campaigns
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of Some Therapies
    • 3.4. Market Trends
      • 3.4.1. Rising Clinical Trials
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Buerger’s Disease Diagnosis, by Type, Treatment, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Buerger’s Disease Diagnosis (Value)
      • 5.2.1. Global Buerger’s Disease Diagnosis by: Type (Value)
        • 5.2.1.1. Blood Tests
        • 5.2.1.2. The Allen’s Test
        • 5.2.1.3. Angiogram (CT Scan, MRI Scan, X-Ray, Others)
        • 5.2.1.4. Tissue Biopsy
        • 5.2.1.5. Others
      • 5.2.2. Global Buerger’s Disease Diagnosis by: Treatment (Value)
        • 5.2.2.1. Smoking Cessation
        • 5.2.2.2. Other Treatments (Medications, Intermittent Compression of the Arms and Legs, Spinal Cord Stimulation, Surgery, Amputation, Therapeutic Angiogenesis, and Others)
      • 5.2.3. Global Buerger’s Disease Diagnosis by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Medical Research Centers
        • 5.2.3.4. Academic Institutes
        • 5.2.3.5. Others
      • 5.2.4. Global Buerger’s Disease Diagnosis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Buerger’s Disease Diagnosis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. FUJIFILM Holdings Corporation (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. General Electric Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Koninklijke Philips N.V. (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pluristem (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Shimadzu Corporation (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Siemens Healthcare GmbH (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. STEMPEUTICS RESEARCH PVT LTD (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Toshiba Medical Corporation (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. T2cure GmbH (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Buerger’s Disease Diagnosis Sale, by Type, Treatment, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Buerger’s Disease Diagnosis (Value)
      • 7.2.1. Global Buerger’s Disease Diagnosis by: Type (Value)
        • 7.2.1.1. Blood Tests
        • 7.2.1.2. The Allen’s Test
        • 7.2.1.3. Angiogram (CT Scan, MRI Scan, X-Ray, Others)
        • 7.2.1.4. Tissue Biopsy
        • 7.2.1.5. Others
      • 7.2.2. Global Buerger’s Disease Diagnosis by: Treatment (Value)
        • 7.2.2.1. Smoking Cessation
        • 7.2.2.2. Other Treatments (Medications, Intermittent Compression of the Arms and Legs, Spinal Cord Stimulation, Surgery, Amputation, Therapeutic Angiogenesis, and Others)
      • 7.2.3. Global Buerger’s Disease Diagnosis by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Medical Research Centers
        • 7.2.3.4. Academic Institutes
        • 7.2.3.5. Others
      • 7.2.4. Global Buerger’s Disease Diagnosis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Buerger’s Disease Diagnosis: by Type(USD Million)
  • Table 2. Buerger’s Disease Diagnosis Blood Tests , by Region USD Million (2015-2020)
  • Table 3. Buerger’s Disease Diagnosis The Allen’s Test , by Region USD Million (2015-2020)
  • Table 4. Buerger’s Disease Diagnosis Angiogram (CT Scan, MRI Scan, X-Ray, Others) , by Region USD Million (2015-2020)
  • Table 5. Buerger’s Disease Diagnosis Tissue Biopsy , by Region USD Million (2015-2020)
  • Table 6. Buerger’s Disease Diagnosis Others , by Region USD Million (2015-2020)
  • Table 7. Buerger’s Disease Diagnosis: by Treatment(USD Million)
  • Table 8. Buerger’s Disease Diagnosis Smoking Cessation , by Region USD Million (2015-2020)
  • Table 9. Buerger’s Disease Diagnosis Other Treatments (Medications, Intermittent Compression of the Arms and Legs, Spinal Cord Stimulation, Surgery, Amputation, Therapeutic Angiogenesis, and Others) , by Region USD Million (2015-2020)
  • Table 10. Buerger’s Disease Diagnosis: by End User(USD Million)
  • Table 11. Buerger’s Disease Diagnosis Hospitals , by Region USD Million (2015-2020)
  • Table 12. Buerger’s Disease Diagnosis Clinics , by Region USD Million (2015-2020)
  • Table 13. Buerger’s Disease Diagnosis Medical Research Centers , by Region USD Million (2015-2020)
  • Table 14. Buerger’s Disease Diagnosis Academic Institutes , by Region USD Million (2015-2020)
  • Table 15. Buerger’s Disease Diagnosis Others , by Region USD Million (2015-2020)
  • Table 16. South America Buerger’s Disease Diagnosis, by Country USD Million (2015-2020)
  • Table 17. South America Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 18. South America Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 19. South America Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 20. Brazil Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 21. Brazil Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 22. Brazil Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 23. Argentina Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 24. Argentina Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 25. Argentina Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 26. Rest of South America Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 27. Rest of South America Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 28. Rest of South America Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 29. Asia Pacific Buerger’s Disease Diagnosis, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 31. Asia Pacific Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 32. Asia Pacific Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 33. China Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 34. China Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 35. China Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 36. Japan Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 37. Japan Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 38. Japan Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 39. India Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 40. India Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 41. India Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 42. South Korea Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 43. South Korea Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 44. South Korea Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 45. Taiwan Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 46. Taiwan Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 47. Taiwan Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 48. Australia Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 49. Australia Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 50. Australia Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 54. Europe Buerger’s Disease Diagnosis, by Country USD Million (2015-2020)
  • Table 55. Europe Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 56. Europe Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 57. Europe Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 58. Germany Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 59. Germany Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 60. Germany Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 61. France Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 62. France Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 63. France Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 64. Italy Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 65. Italy Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 66. Italy Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 67. United Kingdom Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 68. United Kingdom Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 69. United Kingdom Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 70. Netherlands Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 71. Netherlands Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 72. Netherlands Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 73. Rest of Europe Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 74. Rest of Europe Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 75. Rest of Europe Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 76. MEA Buerger’s Disease Diagnosis, by Country USD Million (2015-2020)
  • Table 77. MEA Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 78. MEA Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 79. MEA Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 80. Middle East Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 81. Middle East Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 82. Middle East Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 83. Africa Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 84. Africa Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 85. Africa Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 86. North America Buerger’s Disease Diagnosis, by Country USD Million (2015-2020)
  • Table 87. North America Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 88. North America Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 89. North America Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 90. United States Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 91. United States Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 92. United States Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 93. Canada Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 94. Canada Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 95. Canada Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 96. Mexico Buerger’s Disease Diagnosis, by Type USD Million (2015-2020)
  • Table 97. Mexico Buerger’s Disease Diagnosis, by Treatment USD Million (2015-2020)
  • Table 98. Mexico Buerger’s Disease Diagnosis, by End User USD Million (2015-2020)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Buerger’s Disease Diagnosis: by Type(USD Million)
  • Table 109. Buerger’s Disease Diagnosis Blood Tests , by Region USD Million (2021-2026)
  • Table 110. Buerger’s Disease Diagnosis The Allen’s Test , by Region USD Million (2021-2026)
  • Table 111. Buerger’s Disease Diagnosis Angiogram (CT Scan, MRI Scan, X-Ray, Others) , by Region USD Million (2021-2026)
  • Table 112. Buerger’s Disease Diagnosis Tissue Biopsy , by Region USD Million (2021-2026)
  • Table 113. Buerger’s Disease Diagnosis Others , by Region USD Million (2021-2026)
  • Table 114. Buerger’s Disease Diagnosis: by Treatment(USD Million)
  • Table 115. Buerger’s Disease Diagnosis Smoking Cessation , by Region USD Million (2021-2026)
  • Table 116. Buerger’s Disease Diagnosis Other Treatments (Medications, Intermittent Compression of the Arms and Legs, Spinal Cord Stimulation, Surgery, Amputation, Therapeutic Angiogenesis, and Others) , by Region USD Million (2021-2026)
  • Table 117. Buerger’s Disease Diagnosis: by End User(USD Million)
  • Table 118. Buerger’s Disease Diagnosis Hospitals , by Region USD Million (2021-2026)
  • Table 119. Buerger’s Disease Diagnosis Clinics , by Region USD Million (2021-2026)
  • Table 120. Buerger’s Disease Diagnosis Medical Research Centers , by Region USD Million (2021-2026)
  • Table 121. Buerger’s Disease Diagnosis Academic Institutes , by Region USD Million (2021-2026)
  • Table 122. Buerger’s Disease Diagnosis Others , by Region USD Million (2021-2026)
  • Table 123. South America Buerger’s Disease Diagnosis, by Country USD Million (2021-2026)
  • Table 124. South America Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 125. South America Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 126. South America Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 127. Brazil Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 128. Brazil Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 129. Brazil Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 130. Argentina Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 131. Argentina Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 132. Argentina Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 133. Rest of South America Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 134. Rest of South America Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 135. Rest of South America Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 136. Asia Pacific Buerger’s Disease Diagnosis, by Country USD Million (2021-2026)
  • Table 137. Asia Pacific Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 138. Asia Pacific Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 139. Asia Pacific Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 140. China Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 141. China Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 142. China Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 143. Japan Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 144. Japan Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 145. Japan Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 146. India Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 147. India Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 148. India Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 149. South Korea Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 150. South Korea Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 151. South Korea Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 152. Taiwan Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 153. Taiwan Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 154. Taiwan Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 155. Australia Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 156. Australia Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 157. Australia Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 161. Europe Buerger’s Disease Diagnosis, by Country USD Million (2021-2026)
  • Table 162. Europe Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 163. Europe Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 164. Europe Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 165. Germany Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 166. Germany Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 167. Germany Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 168. France Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 169. France Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 170. France Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 171. Italy Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 172. Italy Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 173. Italy Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 174. United Kingdom Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 175. United Kingdom Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 176. United Kingdom Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 177. Netherlands Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 178. Netherlands Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 179. Netherlands Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 180. Rest of Europe Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 181. Rest of Europe Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 182. Rest of Europe Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 183. MEA Buerger’s Disease Diagnosis, by Country USD Million (2021-2026)
  • Table 184. MEA Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 185. MEA Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 186. MEA Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 187. Middle East Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 188. Middle East Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 189. Middle East Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 190. Africa Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 191. Africa Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 192. Africa Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 193. North America Buerger’s Disease Diagnosis, by Country USD Million (2021-2026)
  • Table 194. North America Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 195. North America Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 196. North America Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 197. United States Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 198. United States Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 199. United States Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 200. Canada Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 201. Canada Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 202. Canada Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 203. Mexico Buerger’s Disease Diagnosis, by Type USD Million (2021-2026)
  • Table 204. Mexico Buerger’s Disease Diagnosis, by Treatment USD Million (2021-2026)
  • Table 205. Mexico Buerger’s Disease Diagnosis, by End User USD Million (2021-2026)
  • Table 206. Research Programs/Design for This Report
  • Table 207. Key Data Information from Secondary Sources
  • Table 208. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Buerger’s Disease Diagnosis: by Type USD Million (2015-2020)
  • Figure 5. Global Buerger’s Disease Diagnosis: by Treatment USD Million (2015-2020)
  • Figure 6. Global Buerger’s Disease Diagnosis: by End User USD Million (2015-2020)
  • Figure 7. South America Buerger’s Disease Diagnosis Share (%), by Country
  • Figure 8. Asia Pacific Buerger’s Disease Diagnosis Share (%), by Country
  • Figure 9. Europe Buerger’s Disease Diagnosis Share (%), by Country
  • Figure 10. MEA Buerger’s Disease Diagnosis Share (%), by Country
  • Figure 11. North America Buerger’s Disease Diagnosis Share (%), by Country
  • Figure 12. Global Buerger’s Disease Diagnosis share by Players 2020 (%)
  • Figure 13. Global Buerger’s Disease Diagnosis share by Players (Top 3) 2020(%)
  • Figure 14. Global Buerger’s Disease Diagnosis share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. FUJIFILM Holdings Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 17. FUJIFILM Holdings Corporation (Japan) Revenue: by Geography 2020
  • Figure 18. General Electric Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. General Electric Company (United States) Revenue: by Geography 2020
  • Figure 20. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 21. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2020
  • Figure 22. Pluristem (Israel) Revenue, Net Income and Gross profit
  • Figure 23. Pluristem (Israel) Revenue: by Geography 2020
  • Figure 24. Shimadzu Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Shimadzu Corporation (Japan) Revenue: by Geography 2020
  • Figure 26. Siemens Healthcare GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Siemens Healthcare GmbH (Germany) Revenue: by Geography 2020
  • Figure 28. STEMPEUTICS RESEARCH PVT LTD (India) Revenue, Net Income and Gross profit
  • Figure 29. STEMPEUTICS RESEARCH PVT LTD (India) Revenue: by Geography 2020
  • Figure 30. Toshiba Medical Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Toshiba Medical Corporation (Japan) Revenue: by Geography 2020
  • Figure 32. T2cure GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 33. T2cure GmbH (Germany) Revenue: by Geography 2020
  • Figure 34. Global Buerger’s Disease Diagnosis: by Type USD Million (2021-2026)
  • Figure 35. Global Buerger’s Disease Diagnosis: by Treatment USD Million (2021-2026)
  • Figure 36. Global Buerger’s Disease Diagnosis: by End User USD Million (2021-2026)
  • Figure 37. South America Buerger’s Disease Diagnosis Share (%), by Country
  • Figure 38. Asia Pacific Buerger’s Disease Diagnosis Share (%), by Country
  • Figure 39. Europe Buerger’s Disease Diagnosis Share (%), by Country
  • Figure 40. MEA Buerger’s Disease Diagnosis Share (%), by Country
  • Figure 41. North America Buerger’s Disease Diagnosis Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • FUJIFILM Holdings Corporation (Japan)
  • General Electric Company (United States)
  • Koninklijke Philips N.V. (Netherlands)
  • pluristem (Israel)
  • Shimadzu Corporation (Japan)
  • Siemens Healthcare GmbH (Germany)
  • STEMPEUTICS RESEARCH PVT LTD (India)
  • Toshiba Medical Corporation (Japan)
  • t2cure GmbH (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation